Condensed Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:
Net income	$ 194,834	$ 150,746
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation expense	4,041	4,400
Amortization of patents	19,593	19,375
Common stock and options for compensation, consulting and vendor services	88,052	280,610
Accrued interest expense on notes payable		24,419
Bad debt reversal		(55,987)
Loss on Earnings on Medical Joint Venture	130,523
Loss on Earnings on Education Joint Venture	3,416
Changes in operating assets and liabilities:
Decrease (Increase) in accounts receivable	311,481	(246,594)
(Increase) Decrease in inventories	(423,294)	13,012
Decrease to advance on contracts	326,197	39,756
(Increase) Decrease to prepaid expenses and other current assets	(50,866)	73,119
Decrease in accounts payable	(803,233)	(306,322)
Increase in customer advances	507,345
Decrease in accrued expenses	(31,121)	(80,201)
Net cash provided by (used in) operating activities	276,968	(83,667)
Cash flows from investing activities:
Investment in Medical Joint Venture	(58,703)
Investment in Education Joint Venture		(50,000)
Purchases of property and equipment	(4,616)	(856)
Payment for patents rights		(9,122)
Net cash used in investing activities	(63,319)	(59,978)
Cash flows from financing activities:
Proceeds from exercise of stock options	38,000
Proceeds from the sale of common stock		50,000
Proceeds from loan from related party		50,000
Net cash provided by financing activities	38,000	100,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	251,649	(43,645)
Cash and cash equivalents at beginning of period	1,147,198	165,249
Cash and cash equivalents at end of period	1,398,847	121,604
Supplemental disclosure on non cash investing and financing activities:
Shares issued to employees in lieu of cash compensation	11,875	11,875
Shares to be issued to directors for prepaid directors' fees	$ 55,200